Growth-hormone response
Study
Human endocrine studies show acute GH release.4
Hormonal
Hexarelin
Growth-hormone secretagogue
Investigational; no FDA-approved hexarelin product identified.
What does it do?
Molecular information
3Amino-acid sequence
- His
- D-MeTrp
- Ala
- Trp
- D-Phe
- Lys
6 residues · N → C3
Length6 amino acids
Molecular weight · Da887.0 Da
Molecular formulaC47H58N12O63
H–dMeW–A–W–dF–KdMeW = D-2-methyltryptophan; dF = D-phenylalanine. C-terminal amide.
Amidated hexapeptide; parent mass excludes salt counterions.
Pharmacokinetics
Unverified reference estimateNot independently confirmed
Reference half-life1 hour22
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 5 h
Five half-lives in this estimated model. This is not a prediction of when effects stop.
About this estimate
Population: Not established by the reference estimate
Source’s stated attribution: Imbimbo et al. 1994
Source’s reported peak time: 30 min. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Acute GH release
A 12-man placebo-controlled dose-response study observed GH peaks around 30 minutes after IV dosing. This measures hormone response, not recovery.4
No demonstrated body-composition change
After 16 weeks, fat mass, lean mass, bone density and IGF-I did not significantly change in the cited study.1
Doses & schedules
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous injection | 1.5 μg/kg | Twice daily | Assess sustained GH-axis effectsAdults; participant count not stated in the indexed abstractHuman study | 16 weeks, with reassessment 4 weeks after stopping | 1 |
Population Adults; participant count not stated in the indexed abstract Context GH response attenuated during treatment and recovered after withdrawal. | |||||
| SubQ | 100 mcg | 3x daily (morning, midday, evening) | GH OptimizationReference report | 8-16 weeks maximum | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. WADA prohibition and desensitization claims do not make community cycles clinically established. Interaction labels are source claims. Source tabs Injectable / Nasal | |||||
| SubQ | 100-200 mcg | 2x daily | Cardioprotection ResearchReference report | 8-16 weeks maximum | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. WADA prohibition and desensitization claims do not make community cycles clinically established. Interaction labels are source claims. Source tabs Injectable / Nasal | |||||
| SubQ | 100 mcg | 2x daily (morning and bedtime) | Recovery/Anti-AgingReference report | 8-16 weeks maximum | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. WADA prohibition and desensitization claims do not make community cycles clinically established. Interaction labels are source claims. Source tabs Injectable / Nasal | |||||
| SubQ | 100 mcg hexarelin + 100 mcg CJC-1295 | 2-3x daily | With GHRH (Synergistic)Reference report | 8-16 weeks maximum | 23 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. WADA prohibition and desensitization claims do not make community cycles clinically established. Interaction labels are source claims. Source tabs Injectable / Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable / Nasal
- Use period
- 8-16 weeks maximum
- Break
- 4-6 weeks mandatory to restore GH response and prevent tolerance
Reported timing
Morning upon waking, midday (optional), and 30 minutes before bed. Administer on empty stomach.
Side effects & safety
Other hormone effects
Human testing found ACTH and cortisol stimulation as well as GH release; responses differed in people with Cushing’s disease.
2Desensitization
The GH response decreased during 16 weeks of repeated dosing and recovered after withdrawal.
1Limited clinical safety scope
Short endocrine experiments and a 16-week study do not establish long-term safety for community recovery regimens.
41Hormonal/metabolic effects
Cortisol/prolactin elevation, edema, glucose disruption and possible hypogonadism; active cancer requires particular caution.
Stop symptoms
Hand numbness/joint pain, persistent edema, breast symptoms, fatigue, hyperglycemia, headache/vision changes or allergy.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
11 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
GHRP-6
Caution reportedOverlapping hormonal action.23
Reference report · Pep-Pedia label: Use CautionGHRP-2
Caution reportedOverlapping hormonal action.23
Reference report · Pep-Pedia label: Use CautionCJC-1295 with DAC
Caution reportedProlonged exposure concern.23
Reference report · Pep-Pedia label: Use CautionMK-677
Caution reportedOverlapping receptor stimulation.23
Reference report · Pep-Pedia label: Monitor CombinationHGH
Avoidance reportedExcess GH concern.23
Reference report · Pep-Pedia label: Avoid CombinationCJC-1295 without DAC
Unverified pairingComplementary receptor action.23
Reference report · Pep-Pedia label: SynergisticSermorelin
Unverified pairingGH-response research.23
Reference report · Pep-Pedia label: SynergisticIpamorelin
Unverified pairingClaim of softened side effects unproven.23
Reference report · Pep-Pedia label: CompatibleTesamorelin
Unverified pairingGHRH-class extrapolation.23
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingSafety unestablished.23
Reference report · Pep-Pedia label: CompatibleOther growth-hormone secretagogues
Not establishedSingle-compound studies do not validate community stacking. The long-term study also shows that response can attenuate with repeated exposure.1
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
No formulation-specific human reconstitution instructions were verified for this research powder.1
Diluent and storage
A compatible solvent, concentration, preservative and beyond-use period cannot be inferred from vial mass. The cited source does not validate a universal bacteriostatic-water recipe.1
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia provides two vial concentration examples.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- 2 mg in 2 mL gives 1 mg/mL; 5 mg in 2.5 mL gives 2 mg/mL. · At 0.1 mL, these contain 100 mcg and 200 mcg respectively. · Reported storage: 2–8°C.
The source describes gentle mixing and avoiding vigorous shaking.
Nasal
The nasal tab repeats the injectable vial and syringe examples.
The source describes gentle mixing and avoiding vigorous shaking.
It does not establish nasal formulation compatibility or pump delivery volume.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceThird-party COA verificationReported appearanceProper cold chain shippingReported appearanceVacuum-sealed vialsReported variationMonitor for desensitizationReported variationCortisol and prolactin effectsReported concernPre-mixed solutionsReported concernDiscolored or cloudy solution
23Vial sizes
5mg9
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage notes
23Refrigerate at 2-8°C immediately after reconstitution. Use within 4 weeks.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Evidence limits
View findings →Clinically meaningful recovery, strength, cardiovascular, or longevity benefit.1
5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Limited human dataSource context
WADA prohibition and desensitization claims do not make community cycles clinically established. Interaction labels are source claims.
Compound identity & other names
Hexarelin is a growth-hormone secretagogue studied in small human endocrine experiments. It can raise GH, but repeated administration can blunt the response, and a longer study did not show significant lean-mass or fat changes.
Other names: Examorelin · HEX · Hexarelin (Examorelin)
Investigational; no FDA-approved hexarelin product identified.
Examorelin / hexarelin: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2.3
Pep-Pedia identity record
6 amino acids · 887.04 Da
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2Reference description; checked chemical identity takes precedence when available.23
How it may work
GHS-R1a stimulation plus CD36-related cardiac signaling; nasal exposure is less predictable than injection.23
The GH response waned during repeated treatment
After 16 weeks of twice-daily administration, the GH response to a challenge was lower and recovered after four weeks off. IGF-I, total fat, lean mass, and bone mineral density did not significantly change.
1Effects extend beyond growth hormone
A human endocrine study found increases in ACTH and cortisol after intravenous hexarelin. The compound is not exclusively a GH signal.
2Recent analytical evidence has a different purpose
A 2025 hepatocyte study identified hexarelin as an alexamorelin metabolite. It informs analytical detection, not hexarelin effectiveness or a human dosing schedule.
7Research areas and evidence gaps
Growth-hormone response research. Human endocrine studies show acute GH release.4
- Clinically meaningful recovery, strength, cardiovascular, or longevity benefit.
- Long-term metabolic and endocrine consequences of community schedules.
Additional uses listed by Pep-Pedia
GH/IGF-1. Hormone release, not demonstrated general anti-aging benefit.23
Cardiac protection. Ischemia and fibrosis models.23
Brain protection. Neurogenesis, oxidative injury and ALS cell-model research.23
Recovery and metabolism. Muscle-preservation, lipid/glucose and exercise claims require clinical confirmation.23
Community reports Unvalidated
PepPedia discusses GH, recovery, and cardioprotection goals; these should not be read as established patient benefits.8
PepPedia's editorial protocol summary, not measured community consensus. Benefits, product identity, and safety are not independently verified; these reported practices are not recommendations.
Search coverage and review status
Added a 2025 hepatocyte metabolite-detection paper; it is not a new human hexarelin treatment trial.
- Checked
- 2026-10-12
- Search
- "hexarelin" "2025" study
- Catalog
- Pep-Pedia ↗ · 14 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “11 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1Growth hormone status during long-term hexarelin therapyAbstract checked
AI-PREPARED SUMMARY
Sixteen weeks of repeated treatment produced reversible attenuation of GH response without significant IGF-I or body-composition changes.
The GH response waned during repeated treatment
After 16 weeks of twice-daily administration, the GH response to a challenge was lower and recovered after four weeks off. IGF-I, total fat, lean mass, and bone mineral density did not significantly change.
2Hexarelin effects on ACTH and cortisolAbstract checked
AI-PREPARED SUMMARY
A monitored endocrine study found significant ACTH and cortisol increases in healthy subjects after intravenous hexarelin.
Effects extend beyond growth hormone
A human endocrine study found increases in ACTH and cortisol after intravenous hexarelin. The compound is not exclusively a GH signal.
3PubChem: Examorelin, CID 6918297Primary source checked
AI-PREPARED SUMMARY
Defines hexarelin’s six-residue sequence, parent formula and average molecular weight 887.0 g/mol.
4Imbimbo et al.: Human hexarelin dose-response studyAbstract checked
AI-PREPARED SUMMARY
Twelve men received escalating IV hexarelin and placebo. GH peaked at about 30 minutes; the reported 55-minute half-life concerns GH, not the administered peptide.
5Growth Hormone-Releasing Activity of Hexarelin in Humans (1994)Abstract checked
AI-PREPARED SUMMARY
Twelve men received escalating IV hexarelin and placebo. GH peaked at about 30 minutes; the reported 55-minute half-life concerns GH, not the administered peptide.
Pep-Pedia bibliography · Checked 2026-10-12
6Growth hormone-releasing activity of hexarelin in humans: a dose-response studyAbstract checked
AI-PREPARED SUMMARY
Twelve men received escalating IV hexarelin and placebo. GH peaked at about 30 minutes; the reported 55-minute half-life concerns GH, not the administered peptide.
Pep-Pedia bibliography · Checked 2026-10-12
7Identification of alexamorelin consumption biomarkers using human hepatocyte incubations and high-resolution mass spectrometryAbstract checked
AI-PREPARED SUMMARY
Examorelin, also called hexarelin, was identified as an alexamorelin metabolite in hepatocyte incubations. This analytical study is not a clinical hexarelin treatment trial.
Recent analytical evidence has a different purpose
A 2025 hepatocyte study identified hexarelin as an alexamorelin metabolite. It informs analytical detection, not hexarelin effectiveness or a human dosing schedule.
Additional research · Checked 2026-10-12
8PepPedia: reported practices (accessed October 12, 2026)Community source checked
AI-PREPARED SUMMARY
Secondary editorial account of discussed practices; not a clinical trial or representative survey.
9Research catalog: labeled quantitiesCatalog checked
AI-PREPARED SUMMARY
Lists a 5 mg lyophilized research vial. Quantity examples only; vendor quality and suitability are not endorsed.
10Hexarelin Treatment Preserves Myocardial Function After MI (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Infarcted mice had better ventricular function and about 53% less ventricular collagen, with lower inflammatory markers.
Reported population / model
Mouse model
Reported study details
0.3 mg/kg/day SubQ · 21 days · LAD ligation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Protective Effects of Hexarelin in ALS Neuroblastoma Model (2023)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Mutant-SOD1 neuroblastoma cells showed less peroxide injury and DNA-damage signaling; this was not an ALS patient study.
Reported population / model
In vitro
Reported study details
1 μM · Human neuroblastoma cells · SOD1-G93A mutation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Cardiovascular Action of Hexarelin Review (2014)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The review describes CD36-mediated cardiac effects independent of GH and limited human cardiac measurements; clinical outcome benefit is unproven.
Reported population / model
Review
Reported study details
Multiple studies · CD36 receptor mechanism
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13Hexarelin Desensitization Study (2000)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: GH response declined during 16 weeks in 12 older people and returned toward baseline four weeks after stopping.
Reported population / model
Human
Reported study details
SubQ twice daily · 16 weeks · 12 elderly subjects
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Hexarelin Pharmacokinetics in Rats (1999)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Rat IV half-life was reported as 75.9 minutes; clearance and accumulation results cannot be assumed for human subcutaneous use.
Reported population / model
Rat model
Reported study details
IV and SubQ · Multiple doses · PK analysis
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
15Hexarelin preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarctionPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Infarcted mice had better ventricular function and about 53% less ventricular collagen, with lower inflammatory markers.
Reported population / model
Mouse model
Reported study details
0.3 mg/kg/day SubQ · 21 days · LAD ligation
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16Protective Effects of Hexarelin and JMV2894 in a Human Neuroblastoma Cell Line Expressing SOD1-G93ALinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
17Chronic administration of hexarelin attenuates cardiac fibrosis in spontaneously hypertensive ratsLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
18Growth hormone-independent cardioprotective effects of hexarelin in the ratLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
19Growth hormone secretagogues and the regulation of calcium signaling in muscleLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
20The cardiovascular action of hexarelinLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
21Growth hormone secretagogues: history, mechanism of action, and clinical developmentLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
22Pep-Pedia: Hexarelin — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 1 hr and a peak time of 30 min. Stated attribution: Imbimbo et al. 1994. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
23Pep-Pedia: Hexarelin — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12